Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Price

NNNNStock

$7.83−84.16%52W

Market Cap$343.67M

P/E230.55x

PEG Ratio—

Div yield—

Beta1.53

NNNN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-81.08%

Price vs S&P 500 (4W)-25.22%

VGM Score24.99

P/E Ratio (Annual)230.55x

P/CF (Annual)1994.73x

Book Value / Share (Quarterly)$0.21

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-28.39%

Cash Flow / Share (Quarterly)$0.01

Price vs S&P 500 (YTD)-85.69%

Gross Margin (TTM)89.00%

Net Profit Margin (TTM)77.10%

EPS (TTM)$0.23

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$0.23

EPS (Annual)$0.15

ROI (Annual)21.24%

Gross Margin (Annual)87.24%

Net Profit Margin (5Y Avg)47.28%

Cash / Share (Quarterly)$0.08

P/E Basic Excl Extra (TTM)144.72x

Revenue Growth QoQ (YoY)5.64%

P/E Normalized (Annual)230.55x

ROA (Last FY)21.17%

Revenue Growth TTM (YoY)-5.72%

EBITD / Share (TTM)$0.13

ROE (5Y Avg)46.01%

Operating Margin (TTM)69.04%

Cash Flow / Share (Annual)$-0.05

P/B Ratio48.96x

P/B Ratio (Quarterly)143.49x

Net Income / Employee (Annual)$237,200

Net Interest Coverage (TTM)44.91x

ROA (TTM)35.22%

EPS Growth QoQ (YoY)161.32%

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)344.29x

Quick Ratio (Quarterly)177.11x

3-Month Avg Trading Volume0.06M

52-Week Price Return-84.16%

EV / Free Cash Flow (Annual)1992.16x

P/E Incl Extra (TTM)144.72x

Revenue / Employee (TTM)$490,100

P/S Ratio (Annual)170.74x

Asset Turnover (Annual)0.29x

52-Week High$52.93

Operating Margin (5Y Avg)43.81%

EPS Excl Extra (Annual)$0.15

26-Week Price Return-69.84%

Quick Ratio (Annual)177.12x

13-Week Price Return-73.88%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)344.29x

Enterprise Value$1.47B

Asset Turnover (TTM)0.46x

Revenue / Employee (Annual)$320,300

Pretax Margin (Annual)74.06%

Cash / Share (Annual)$0.08

3-Month Return Std Dev111.30%

Gross Margin (5Y Avg)63.99%

Net Income / Employee (TTM)$377,800

ROE (Last FY)21.24%

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)709.64x

Receivables Turnover (TTM)5.61x

EV / Free Cash Flow (TTM)705.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.23

Receivables Turnover (Annual)3.66x

ROI (TTM)35.36%

P/S Ratio (TTM)111.58x

Pretax Margin (5Y Avg)47.28%

Revenue / Share (Annual)$0.20

Price vs S&P 500 (52W)-102.47%

P/E Ratio (TTM)144.72x

EPS Growth TTM (YoY)69.57%

Year-to-Date Return-73.73%

5-Day Price Return-5.39%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)34.25%

Net Profit Margin (Annual)74.06%

Month-to-Date Return-20.20%

EBITD / Share (Annual)$0.13

EPS Growth (3Y)-13.70%

Operating Margin (Annual)66.70%

P/CF (TTM)709.64x

ROI (5Y Avg)46.01%

P/E Excl Extra (TTM)144.72x

EPS Basic Excl Extra (TTM)$0.23

P/B Ratio (Annual)143.49x

Pretax Margin (TTM)77.10%

Book Value / Share (Annual)$0.21

Price vs S&P 500 (13W)-76.68%

Beta1.53x

P/FCF (Annual)709.64x

Revenue / Share (TTM)$0.30

ROE (TTM)35.36%

52-Week Low$6.61

vGradeF

gGradeB

mGradeF

vgmGradeD

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	F	$7.83
IDXXIdexx Laboratories Inc	D	B	C	$550.01
LNTHLantheus Holdings, Inc	C	B	B	$100.87
CLDXCelldex Therapeutics, Inc	F	F	B	$41.22
NEOGNeogen Corp	C	C	B	$11.64
NTLAIntellia Therapeutics, Inc	D	D	C	$13.51
QDELQuidelOrtho Corporation Common Stock	C	C	C	$15.05
ACHVAchieve Life Sciences, Inc.	F	F	A	$8.17
TKNOAlpha Teknova, Inc. Common Stock	D	C	A	$7.46
MYGNMyriad Genetics Inc	B	C	D	$3.19
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$4.44
ICCCImmucell Corp	C	B	B	$9.84
QCLSQ/C Technologies, Inc. Common Stock	C	—	F	$2.44
TRIBTrinity Biotech plc	B	D	F	$9.71
CDIOCardio Diagnostics Holdings Inc. Common stock	—	C	B	$1.91
BMRABIOMERICA INC	B	D	D	$1.77
VNRXVolitionRx Limited	B	A	F	$0.38
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	D	$2.91
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	C	$0.01

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is an in vitro diagnostics company offering laboratory, point-of-care, and at-home testing solutions across infectious diseases, oncology, cardiovascular health, and other clinical domains. Its product portfolio includes automated analyzers such as the AF-1200 fluorescence immunoassay and SHA-100 dry chemistry systems, along with rapid diagnostic kits for conditions including COVID-19, dengue, and hepatitis. The company generates revenue primarily from Europe, with significant presence in South America and Asia-Pacific.